FDA plans to eye "corrective" DTC

Share this article:

FDA has outlined plans to study the use of corrective DTC TV ads as a way of remedying deceptive advertising. The agency wants to know how exposure to a combination of original and corrective ads affects message recall, message comprehension, perceived efficacy and risk and intent to ask a doctor about the drug. It also wants to find out how comprehension might relate to theme and visual elements in the advertisements as well as to the length of delay between the original ad and the corrective ad.

The agency plans to conduct 6,650 online interviews for the study. Ads will feature fake products for asthma and weight loss.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Agency Gallery

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters